Amalgamated Bank Sells 214 Shares of Chemed Co. (NYSE:CHE)

Amalgamated Bank decreased its holdings in shares of Chemed Co. (NYSE:CHEFree Report) by 2.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 10,681 shares of the company’s stock after selling 214 shares during the period. Amalgamated Bank owned approximately 0.07% of Chemed worth $5,551,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CHE. BlackRock Inc. grew its holdings in shares of Chemed by 1.5% in the 2nd quarter. BlackRock Inc. now owns 1,415,756 shares of the company’s stock valued at $766,873,000 after buying an additional 21,237 shares during the period. Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Chemed by 1.2% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 516,636 shares of the company’s stock valued at $279,846,000 after buying an additional 6,310 shares during the period. Durable Capital Partners LP grew its holdings in shares of Chemed by 71.2% in the 2nd quarter. Durable Capital Partners LP now owns 457,500 shares of the company’s stock valued at $247,814,000 after buying an additional 190,309 shares during the period. State Street Corp grew its holdings in shares of Chemed by 0.4% in the 2nd quarter. State Street Corp now owns 443,937 shares of the company’s stock valued at $240,467,000 after buying an additional 1,577 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Chemed by 0.3% in the 1st quarter. Wellington Management Group LLP now owns 416,960 shares of the company’s stock valued at $211,210,000 after buying an additional 1,233 shares during the period. Institutional investors own 94.25% of the company’s stock.

Chemed Trading Up 0.7 %

Shares of NYSE CHE opened at $592.79 on Wednesday. The firm has a market cap of $8.93 billion, a PE ratio of 36.71, a PEG ratio of 2.88 and a beta of 0.43. Chemed Co. has a 1-year low of $490.87 and a 1-year high of $610.35. The company has a fifty day moving average price of $584.29 and a 200 day moving average price of $549.42.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada boosted their price target on shares of Chemed from $576.00 to $604.00 and gave the company an “outperform” rating in a report on Monday, October 30th. Oppenheimer upped their target price on shares of Chemed from $590.00 to $625.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 17th.

Check Out Our Latest Report on Chemed

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 1,500 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $572.77, for a total transaction of $859,155.00. Following the sale, the chief executive officer now directly owns 111,468 shares of the company’s stock, valued at approximately $63,845,526.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Chemed news, EVP Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $579.73, for a total transaction of $579,730.00. Following the sale, the executive vice president now directly owns 22,568 shares of the company’s stock, valued at approximately $13,083,346.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin J. Mcnamara sold 1,500 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $572.77, for a total transaction of $859,155.00. Following the sale, the chief executive officer now directly owns 111,468 shares in the company, valued at $63,845,526.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,314 shares of company stock valued at $6,579,059. Company insiders own 3.80% of the company’s stock.

Chemed Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

See Also

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.